A constellation of regulations, standards, and protocols control the medical device production arena, among which the United States’ Federal Drug Administration (FDA) and International Organization for Standardization’s (ISO) stipulations play crucial roles. Specifically, the FDA’s 21 CFR Part 820 and ISO 13485 commands extensive respect and observance due to their core focus on maintaining quality systems within this industry. Therefore, the proper comprehension and subsequent proper application of these two critical standards become a matter of immense importance to industry professionals.
The implementation of the FDA’s 21 CFR Part 820 ensures that the manufacturing of finished medical devices accords with the Federal Food, Drug, and Cosmetic Act (FD&C Act), enabling facilities to sustain their regulatory compliance. This regulation underscores the fundamental principles of current good manufacturing practices (CGMP) and requires all facilities engaged in activities related to medical device manufacturing or importation to adhere to a quality management system (QMS) set by federal agencies.
Even though ISO stands as a nongovernmental organization, its ISO 13485 standard covering a QMS for global medical device manufacturing facilities holds significant value. The global recognition, coupled with its bearing on European Union requirements like EU-MDR and EU-IVDR, necessitates the device manufacturers to register to the ISO 13485 standard, especially those exporting devices to international markets. Recently, the FDA declared forthcoming changes to be in effect by February 2, 2026, with the integration of ISO 13485 standards into 21 CFR 820.
The joint harmonization of these two significant regulatory standards is designed with the purpose of streamlining the system, hastening delivery of new devices, and also augmenting cost savings throughout the sector, ultimately contributing to improved patients’ quality of life. Naturally, overarching global collaboration of this magnitude kindles concerns and discussions around the finer details, such as specific terminologies. In response, the FDA, as part of this transparent consultation process, has agreed to add the term ‘correction’ to align more closely with ISO 13485.
While the upcoming harmonized Quality Management System Regulation (QMSR) will inherently encompass ISO 13485 standards, it should be noted that it may not cover all current 21 CFR 820 regulation requirements. Therefore, ahead of this big change, professionals should familiarize themselves with ISO 13485 to prepare for this pivotal transition. Arguably, the introduction of new requirements can stir up apprehensions. However, it essential to remember that such evolution and constant refining of the quality system is a cornerstone of reliable and safe medical device production.